Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Compass Trial Investigators"'
Autor:
Andrew Tonkin, Sylvanus Fonguh, Scott D. Berkowitz, John W. Eikelboom, Compass Trial Investigators, Salim Yusuf, Sonia S. Anand, Thomas Vanassche, John Varigos, Jonathan Sen, John Amerena, Keith A.A. Fox, Peter Verhamme
Background The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial showed that rivaroxaban plus aspirin reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease (CAD) and/or p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::755ffc318d16b4b6767679bdfa7f9cfd
https://lirias.kuleuven.be/handle/123456789/675565
https://lirias.kuleuven.be/handle/123456789/675565
Autor:
Mariam Alboom, Nicolas Noiseux, Tej Sheth, Xin Chen, Yusuf Salim, Ingrid Copland, Miroslav Brtko, Louis-Mathieu Stevens, Andre Lamy, François Dagenais, Compass Trial Investigators, Shun Fu Lee, Faisal G Bakeen, Zhe Zheng, Austin Browne, John W. Eikelboom
Publikováno v:
JAMA Cardiol
Importance The relative safety and patency of skeletonized vs pedicled internal mammary artery grafts in patients undergoing coronary artery bypass graft (CABG) surgery are unknown. Objective To investigate the association of skeletonized vs pedicled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b0f1ace8772fe916607482587820015
https://europepmc.org/articles/PMC8209583/
https://europepmc.org/articles/PMC8209583/
Autor:
Nancy Cook Bruns, Sonia S. Anand, Keith A.A. Fox, Stuart J. Connolly, Compass Trial Investigators, Jackie Bosch, Christoph Neumann, Leanne Dyal, Deepak L. Bhatt, Jeffrey L. Probstfield, John W. Eikelboom, Alvaro Avezum, Salim Yusuf, Petr Widimsky
Publikováno v:
Journal of the American College of Cardiology. 73:3271-3280
Background The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial showed that the combination of low-dose rivaroxaban and aspirin reduced major vascular events in patients with stable vascular disease. Objectives The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e8e07b7636ca481664828366051b9e2
https://doi.org/10.1016/j.jacc.2019.02.079
https://doi.org/10.1016/j.jacc.2019.02.079
Autor:
Stuart J. Connolly, Jackie Bosch, Yan Liang, Lars Keller, Eva Muehlhofer, Gilles R. Dagenais, Lisheng Liu, Scott D. Berkowitz, Tomasz J. Guzik, Compass Trial Investigators, Martin O'Donnell, Jun Zhu, Olga Shestakovska, Sonia S. Anand, John W. Eikelboom, Keith A.A. Fox, Salim Yusuf
Aims The COMPASS trial demonstrated that the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events (MACE) in patients with chronic coronary arte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e29bba9d3f03afdc66622741c392a8b
https://ruj.uj.edu.pl/xmlui/handle/item/274064
https://ruj.uj.edu.pl/xmlui/handle/item/274064
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
K.A.A Fox, S. Fonguh, Salim Yusuf, Compass Trial Investigators, J. Sen, John Amerena, John Varigos, Sonia S. Anand, Andrew Tonkin, John W. Eikelboom, Scott D. Berkowitz, Thomas Vanassche, Peter Verhamme
Publikováno v:
European Heart Journal. 41
Background The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial demonstrated that the combination therapy of rivaroxaban and aspirin reduced major adverse cardiovascular events (MACE) compared to aspirin alone in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70568c8dcd6e427f360918227ac89673
https://doi.org/10.1093/ehjci/ehaa946.2906
https://doi.org/10.1093/ehjci/ehaa946.2906
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.